跳至主要内容
临床试验/NCT04361760
NCT04361760已完成不适用

Better to Focus or to Spread? Signal Propagation and Its Relationship to Cognitive Performance in the Aging Human Brain

Insel Gruppe AG, University Hospital Bern1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2020年6月25日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
40
试验地点
1
主要终点
Age-related differences in the spatio-temporal patterns of signal propagation

研究概览

简要总结

In the next three decades, the world's population over 60 years old is expected to more than double its size. Even in the absence of an obvious pathology (i.e., healthy aging), advancing age is typically associated with a progressive decline in cognitive performance. Although pathophysiological changes in age-related neurodegenerative disorders have received much attention over the past years, far less is known about the neural processes affecting cognition in healthy ageing. One of these postulated processes is neural dedifferentiation (i.e., a decrease in neural selectivity, by which neural representations of processed information become less univocally distinguishable), possibly accompanied by the recruitment of additional cortical areas in the healthy aging brain. To date, these processes have been extensively studied on the neural level, yet their functional significance for cognitive behaviour remains largely unclear. This project will investigate neural dedifferentiation and its relationship to cognitive performance in the healthy aging brain. To this end, the investigators will use a combination of state-of-the-art technologies including simultaneous transcranial magnetic stimulation (TMS) and high-density electroencephalography (hd-EEG) as well as diffusion tensor imaging (DTI). Perspectives include a better understanding of the relationship between neurophysiological mechanisms and cognitive performance in the healthy aging brain.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Single (Participant)

入排标准

年龄范围
20 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Informed consent as documented by signature
  • •Age between 20-30 or 65-75 years
  • •Neurologically healthy, i.e., with no documented or present neurological disease or brain injury
  • •Normal or corrected-to-normal visual acuity

排除标准

  • •Any instable medical condition, in particular epilepsy (past or present, including seizures or febrile convulsions)
  • •Any surgical intervention to the brain
  • •Heart diseases
  • •Implanted medical devices (e.g., cochlear implants, infusion pumps, neurostimulators, pacemakers)
  • •History of migraine or strong headaches
  • •Sleep deprivation
  • •Presence of non-MRI safe metal in the body
  • •Drug or alcohol abuse
  • •Intake of any medication that is likely to lower seizure threshold
  • •Claustrophobia
  • •For female participants: in order to participate in the study, female participants in reproductive age need to take a pregnancy test (a standard urine pregnancy test will be provided).
  • •For female participants: breastfeeding
  • •Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, etc. of the participant
  • •Lack of knowledge of the German language
  • •Participation in another study with investigational drug within the 30 days preceding and during the present study
  • •Previous enrolment into the current study
  • •Enrolment of the investigator, his/her family members, employees and other dependent persons

研究组 & 干预措施

Healthy younger participants (20-30y)

Experimental

Within-subject design. In a visual discrimination task participants will be asked to identify specific features of visual stimuli (i.e., the gender of a face, or the motion direction of a grating). During this task, single-pulse TMS will be applied in one-third of the trials; sham stimulation will be applied in a further third of the trials; and no stimulation will be applied in the remaining third of the trials, while hd-EEG will be continuously measured. The order of these three stimulation conditions (i.e., single-pulse TMS, sham, or no stimulation, during the 1st, 2nd, or 3rd third of the trials) will be counterbalanced over participants.

干预措施: single-puls TMS (Device)

Healthy younger participants (20-30y)

Experimental

Within-subject design. In a visual discrimination task participants will be asked to identify specific features of visual stimuli (i.e., the gender of a face, or the motion direction of a grating). During this task, single-pulse TMS will be applied in one-third of the trials; sham stimulation will be applied in a further third of the trials; and no stimulation will be applied in the remaining third of the trials, while hd-EEG will be continuously measured. The order of these three stimulation conditions (i.e., single-pulse TMS, sham, or no stimulation, during the 1st, 2nd, or 3rd third of the trials) will be counterbalanced over participants.

干预措施: sham stimulation (Device)

Healthy older participants (65-75y)

Experimental

Within-subject design. In a visual discrimination task participants will be asked to identify specific features of visual stimuli (i.e., the gender of a face, or the motion direction of a grating). During this task, single-pulse TMS will be applied in one-third of the trials; sham stimulation will be applied in a further third of the trials; and no stimulation will be applied in the remaining third of the trials, while hd-EEG will be continuously measured. The order of these three stimulation conditions (i.e., single-pulse TMS, sham, or no stimulation, during the 1st, 2nd, or 3rd third of the trials) will be counterbalanced over participants.

干预措施: single-puls TMS (Device)

Healthy older participants (65-75y)

Experimental

Within-subject design. In a visual discrimination task participants will be asked to identify specific features of visual stimuli (i.e., the gender of a face, or the motion direction of a grating). During this task, single-pulse TMS will be applied in one-third of the trials; sham stimulation will be applied in a further third of the trials; and no stimulation will be applied in the remaining third of the trials, while hd-EEG will be continuously measured. The order of these three stimulation conditions (i.e., single-pulse TMS, sham, or no stimulation, during the 1st, 2nd, or 3rd third of the trials) will be counterbalanced over participants.

干预措施: sham stimulation (Device)

结局指标

主要结局

Age-related differences in the spatio-temporal patterns of signal propagation

时间窗: 2 hours

The spatiotemporal patterns of signal propagation, as measured with a combined TMS-hd-EEG approach, in younger and older healthy participants, reflecting age-related differences on the neural level.

次要结局

  • Association between the performance in a cognitive test battery and patterns of signal propagation in better- and worse-performers(4 hours)
  • Association between the patterns of signal propagation and the structural properties of the white matter(4 hours)
  • Association between the performance in a cognitive test battery and patterns of signal propagation in younger and older participants(4 hours)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
1 期
Extensión multinacional, multicéntrica y de fase abierta con tratamiento activo del estudio MS-LAQ-301 (Allegro) para evaluar la seguridad a largo plazo, la tolerabilidad y el efecto sobre el curso de la enfermedad de la administración oral de laquinimod 0,6mg una vez al día en pacientes con esclerosis múltiple recurrente. -Esclerosis Múltiple Remitente Recurrente (RRMS).MedDRA version: 9.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosis
EUCTR2009-012989-30-ESTeva Pharmaceutical Industries Ltd1,000
进行中(未招募)
1 期
Extensión multinacional, multicéntrica y de fase abierta con tratamiento activo del estudio MS-LAQ-302 (Bravo) para evaluar la seguridad a largo plazo, la tolerabilidad y el efecto sobre el curso de la enfermedad de la administración oral de laquinimod 0,6mg una vez al día en pacientes con esclerosis múltiple recurrente -aquinimod es desarrollado para el tratamiento de la esclerosis múltiple remitente recurrente.
EUCTR2009-015815-42-ESTeva Pharmaceutical Industries Ltd1,245
进行中(未招募)
3 期
A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Eosinophilic EsophagitisEosinophilic esophagitis
JPRN-jRCT2051200140Inoue Tomoyoshi33
已完成
3 期
A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab* (MSB0010718C) plus Best Supportive Care Versus Best Supportive Care Alone as a Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Cancer whose Disease did not Progress after Completion of First-Line Platinum-Containing ChemotherapyUrothelial cancer10038364
NL-OMON55699Pfizer20
进行中(未招募)
3 期
clinical trial in patient with locally advance or metastatic cancer of the urinary tract
CTRI/2017/01/007696Pfizer Inc6